TITLE

Small Cell Lung Cancer

AUTHOR(S)
Sher, Taimur; Dy, Grace K.; Adjei, Alex A.
PUB. DATE
March 2008
SOURCE
Mayo Clinic Proceedings;Mar2008, Vol. 83 Issue 3, p355
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the cancer most commonly associated with various paraneoplastic syndromes, including the syndrome of inappropriate antidiuretic hormone secretion, paraneoplastic cerebellar degeneration, and Lambert-Eaton myasthenic syndrome. Because of the high propensity of small cell lung cancer to metastasize early, surgery has a limited role as primary therapy. Although the disease is highly sensitive to chemotherapy and radiation, cure is difficult to achieve. The combination of platinum and etoposide is the accepted standard chemotherapeutic regimen. It is also the accepted standard therapy in combination with thoracic radiotherapy (TRT) for limited-stage disease. Adding TRT increases absolute survival by approximately 5% over chemotherapy alone. Thoracic radiotherapy administered concurrently with chemotherapy is more efficacious than sequential therapy. Furthermore, the survival benefit is greater if TRT is given early rather than late in the course of chemotherapy. Regardless of disease stage, no relevant survival benefit results from increased chemotherapy dose intensity or dose density, altered mode of administration (eg, alternating or sequential administration) of various chemotherapeutic agents, or maintenance chemotherapy. Prophylactic cranial radiation prevents central nervous system recurrence and can improve survival. In Japan and some other Asian countries, the combination of irinotecan and cisplatin is the standard chemotherapeutic regimen. Clinical trials using thalidomide, gefitinib, imatinib, temsirolimus, and farnesyltransferase inhibitors have not shown clinical benefit. Other novel agents such as bevacizumab have shown promising early results and are being evaluated in larger trials.
ACCESSION #
31154410

 

Related Articles

  • Acquired rhinophyma as a paraneoplastic manifestation of non-small cell lung cancer. Rakusic, Neven; Baricevic, Denis; Rakusic, Nevena; Samarzija, Miroslav; Jakopovic, Marko; Baricevic, Marinka // Wiener Klinische Wochenschrift;Apr2012, Vol. 124 Issue 7/8, p276 

    We report a case of a 58-year-old man who developed rhinophyma caused by non-small cell lung cancer. To the best of our knowledge, rhinophyma as paraneoplastic syndrome associated with non-small cell lung cancer has not been previously reported.

  • VGCC antibody-positive paraneoplastic cerebellar degeneration presenting with positioning vertigo. Ogawa, Emina; Sakakibara, Ryuji; Kawashima, Kengo; Yoshida, Tomoe; Kishi, Masahiko; Tateno, Fuyuki; Kataoka, Manabu; Kawashima, Tatsuo; Yamamoto, Masahiko // Neurological Sciences;Dec2011, Vol. 32 Issue 6, p1209 

    A 70-year-old woman developed paraneoplastic cerebellar degeneration (PCD) due to P/Q-type and N-type voltage-gated calcium channel antibodies and small cell lung cancer, the main clinical manifestations of which were severe positioning vertigo and vomiting. Loss of the visual suppression of...

  • Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. Sabater, Lidia; Höftberger, Romana; Boronat, Anna; Saiz, Albert; Dalmau, Josep; Graus, Francesc // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    The goal of this study is to determine whether patients with paraneoplastic cerebellar degeneration (PCD) and small-cell lung cancer (SCLC) have a specific repertoire of antibodies, if SOX1 antibodies (SOX1-ab) can predict the presence of SCLC, and if antibodies to cell surface antigens occur in...

  • Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. Gill, Sharlene; Murray, Nevin; Dalmau, Josep; Thiessen, Brian // Canadian Journal of Neurological Sciences;Aug2003, Vol. 30 Issue 3, p269 

    Studies the case of a 43-year-old woman diagnosed with small cell lung cancer and a progressive neurologic paraneoplastic syndrome. Past medical history; Presenting signs and symptoms; Diagnostic procedures; Regression of the lung cancer as a direct result of a host immune response directed at...

  • Hyperamylasaemia: don't forget undiagnosed carcinoma. Crook, M. A. // Annals of Clinical Biochemistry;Jan2014, Vol. 51 Issue 1, p5 

    A review of the article "Hyperamylasaemia and dual paraneoplastic syndromes in small cell lung cancer" by K. Akinosoglou and colleagues is presented.

  • Prognostic Significance of Vitamin D Receptor Polymorphisms in Head and Neck Squamous Cell Carcinoma. Hama, Takanori; Norizoe, Chihiro; Suga, Hiroaki; Mimura, Takeshi; Takakuni Kato; Moriyama, Hiroshi; Urashima, Mitsuyoshi // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background: In patients with advanced non-small-cell lung cancer, vitamin D receptor (VDR) polymorphisms and haplotypes are reported to be associated with survival. We hypothesized that a similar association would be observed in patients with head and neck squamous-cell carcinoma (HNSCC)....

  • Photons or Protons: Precision Radiotherapy of Lung Cancer. Auberger, Thomas; Seydl, Karl; Futschek, Tanja; Sztankay, Arpad; Sweeney, Reinhart; Lukas, Peter // Strahlentherapie und Onkologie;Dec2007 Supplement 2, Vol. 183, p3 

    The article examines the factors that contribute to the precision radiotherapy of lung cancer. Methodology-wise, six patients with non small cell lung cancer (NSCLC) and 27 treatment plans were compared for conformal photon therapy. Based on the results, the researchers concluded that comparison...

  • COMMENTARY: Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non-small-cell lung cancer. Ellis, Peter M. // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p31 

    The article comments on a research study focusing on the use of adjuvant vinorelbine plus cisplatin in the treatment of resected non-small-cell lung cancer. Commenting on the study questions are being raised that which patients should receive adjuvant chemotherapy. The author views that in the...

  • Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. Meert, Anne-Pascale; Paesmans, Marianne; Berghmans, Thierry; Martin, Benoît; Mascaux, Céline; Vallot, Frédéric; Verdebout, Jean-Marc; Lafitte, Jean-Jacques; Sculier, Jean-Paul // BMC Cancer;2001, Vol. 1, p5 

    Purpose: A systematic review of the literature was carried out to determine the role of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) . Methods: To be eligible, full published trials needed to deal with SCLC and to have randomly assigned patients to receive PCI or not....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics